News
Novo Nordisk said on Thursday it plans to start late-stage trials of its experimental weight-loss drug, amycretin, in ...
LISBON (Reuters) -U.S. private equity fund Lone Star has decided to sell its 75% stake in Novo Banco to French banking group ...
Novo Nordisk said on Thursday it plans to start late-stage trials of amycretin injection and oral drugs during the first ...
Denmark's Novo Nordisk is partnering with biotech company Deep Apple Therapeutics in a deal worth up to $812 million to ...
French banking group BPCE has emerged as the leading bidder to acquire Portuguese lender Novo Banco SA from Lone Star Funds, ...
The U.S.-listed shares of Danish drugmaker Novo Nordisk rose Tuesday following a report that an activist investor is building ...
Novo Nordisk ( NVO 6.12%) stock, maker of the blockbuster GLP-1 agonist weight-loss drugs Ozempic and Wegovy, jumped a lucky ...
O Banco Santander achou que tinha acertado em cheio no ano passado ao nomear um executivo muito respeitado para se tornar ...
Novo Nordisk (NVO) plans to start a late-stage clinical program next year to test oral and injectable forms of its new ...
7h
GlobalData on MSNNovo Nordisk signs $812m research deal with Deep Apple for non-GLP-1 drugsDeep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.
Novo Nordisk plans to initiate late-stage trials for its next-gen weight-loss drug amycretin in 2026. The trials will include ...
Novo Nordisk today announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results